SHED vs Ro vs PlexusDx (2026): GLP-1 Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re comparing SHED and Ro for cash-pay GLP-1 weight loss, the headline numbers don’t tell the full story. SHED markets compounded format flexibility (injections, drops, lozenges, oral tablets) plus a brand-name pathway with a separate $125/month membership; Ro markets FDA-approved branded medication via an insurance-concierge model with a $99 first-month visit. The two platforms answer different questions and the cost math depends entirely on which lane you choose. This article walks the actual annualized cost across both platforms, the compounded vs FDA-approved branded distinction, the safety considerations that apply to every GLP-1 program, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol sit relative to both — because the choice between SHED, Ro, and PlexusDx isn’t about which company is “better.” It’s about medication source, oversight model, total annual cost, and whether genetics inform your dose before week one.

SHED vs Ro vs PlexusDx — quick decision frame

Three pricing architectures cover the cash-pay GLP-1 market. SHED runs a compounded-flexibility lane (cash-pay only, HSA/FSA accepted) with compounded semaglutide injections from $199/month and a separate brand-name pathway that adds a $125/month Shed Membership on top of medication. Ro runs a membership-plus-medication model: a Ro Body membership starting at $39 first month/$99 thereafter, plus FDA-approved Wegovy or Zepbound dispensed at manufacturer-matched cash prices (typically $149-$289/mo for the medication itself), with a dedicated insurance concierge that submits prior-authorization paperwork to your plan. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared dual-compound at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month) so dose decisions anchor to the patient’s GIPR, FTO, MC4R, and TCF7L2 variants instead of starting from population averages. All three platforms are cash-pay; PlexusDx adds no membership fee.

The real annual cost: SHED vs Ro vs PlexusDx

For a cash-pay patient with no GLP-1 coverage, the math separates the three quickly. SHED’s compounded semaglutide injection at $149-$289/mo works out to roughly $2,388–$3,588/year on the standard tier; the brand-name lane adds the $125/month Shed Membership on top of medication, pushing total spend higher. Ro’s Wegovy pill pathway is around $39 first month plus $149/month medication and $99/month membership thereafter — roughly $2,927/year cash-pay before any insurance benefit. With covered insurance and the Wegovy Savings Offer or Zepbound Savings Card, Ro can drop the medication copay as low as $25/month. PlexusDx ranges from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), and $2,148–$3,900/year on GLP-Squared ($249/mo). Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay below SHED’s standard tier on the lower PlexusDx protocols. If your insurance reliably covers Wegovy or Zepbound at a low copay, Ro’s branded route may be the cheapest. If your insurance doesn’t cover GLP-1s for weight loss — the case for most U.S. commercial plans as of 2026 — PlexusDx’s protocol pricing is meaningfully below SHED at the entry tier and competitive at the higher tiers, with no separate membership fee.

Compounded vs FDA-approved branded — what each platform actually dispenses

This is the substantive medication difference and it’s worth understanding before signing up for any of the three. SHED dispenses both compounded and FDA-approved branded medications through two distinct lanes — the compounded lane includes semaglutide and tirzepatide in injection, drop, lozenge, and oral liposomal tablet formats; the brand-name lane carries Wegovy, Zepbound, and Foundayo (orforglipron, FDA-approved April 1, 2026) at a separate fee structure. Ro in 2026 is primarily focused on FDA-approved branded medication — the Wegovy pill, Wegovy pen, Zepbound pen and KwikPen, and Foundayo — with cash prices matched to LillyDirect, NovoCare, and TrumpRx. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide like SHED’s compounded lane, but offer four delivery formats — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and a dual-compound semaglutide+tirzepatide stack — at protocol-specific dose ranges, paired with an optional genetic baseline. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. The compounded vs branded choice is not about effectiveness of the active ingredient — it’s about FDA approval status of the finished product, supply consistency, and which regulatory framework governs your medication.

Needle-free options and format flexibility

If you specifically don’t want a weekly injection, the three platforms approach the no-needle question very differently. SHED has the broadest compounded no-needle menu — sublingual drops, dissolvable lozenges, and oral liposomal tablets in the compounded lane, plus FDA-approved Wegovy oral tablet and Foundayo (orforglipron, the first daily-pill GLP-1) through the brand-name lane. Ro covers the FDA-approved oral path — Wegovy pill and Foundayo at manufacturer-matched cash pricing — but doesn’t carry compounded oral formats. PlexusDx offers compounded oral options across three protocols: Semaglutide Oral (3mg–24mg daily, six dose levels, from $249/mo), Tirzepatide Oral (5mg–25mg daily, seven dose levels, $279/mo), and the Microdose GLP-1 Protocol at $129/mo flat with four delivery variants (capsule, troche, lozenge, sublingual). For a cash-pay patient who wants a compounded oral GLP-1 at the lowest published price in this comparison, PlexusDx Microdose is structurally hard to beat at $129/mo.

Insurance, prior authorization, and the cash-pay reality

Insurance posture is the structural difference that separates Ro from the other two. Ro doesn’t bill insurance directly, but operates a dedicated insurance concierge that submits prior-authorization paperwork to your commercial carrier and applies the Wegovy Savings Offer or Zepbound Savings Card. With a covered plan, Ro can drop your monthly copay to as low as $25/month on FDA-approved branded medication. Ro also offers a free GLP-1 Insurance Coverage Checker. SHED’s compounded lane is cash-pay only, with HSA and FSA cards accepted; the brand-name lane indicates “insurance or cash-pay options” on its product pages but doesn’t describe a dedicated prior-authorization workflow. PlexusDx is cash-pay across all six Weight Management Protocols, with no membership fee, no insurance billing, and no prior-authorization workflow — HSA and FSA cards are accepted. If using your insurance for FDA-approved branded medication is central to your plan, Ro is the structurally better starting point. If cash-pay is the model that fits your situation — either because your insurance excludes GLP-1s for weight loss or because you prefer predictable monthly pricing without a membership add-on — PlexusDx’s flat protocol pricing is the cleanest of the three.

Safety, side effects, and clinical oversight

All three platforms prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The FDA-labeled side-effect profile is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — this warning attaches to the active ingredient and applies to compounded versions as well as the FDA-approved branded products. The clinical-oversight question differs by platform. Ro routes prescriptions through licensed providers and partner pharmacies, and FDA post-market surveillance applies directly to its Wegovy/Zepbound/Foundayo dispensing. SHED routes through licensed clinicians and uses pharmacies it states meet USP compounding standards, with LegitScript approval. PlexusDx uses licensed U.S. compounding pharmacies and a clinical team that reviews the patient’s genetic test before titration when the test is included — a stratification step neither SHED nor Ro performs.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor that tirzepatide engages), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither SHED nor Ro performs this step — both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors the same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol. If you’ve previously tried a GLP-1 and stalled, plateaued, or struggled with side effects, a genetic baseline is often the missing variable — and it’s the one structural feature PlexusDx offers that the SHED-vs-Ro comparison can’t match.

Which one fits — a four-question frame

Question 1: Does your insurance reliably cover Wegovy or Zepbound at a low copay? If yes, Ro’s insurance concierge plus the Wegovy Savings Offer or Zepbound Savings Card is likely cheapest — copays as low as $25/month are achievable. Question 2: Are you cash-pay with no GLP-1 coverage and price is the dominant factor? Compare SHED’s $2,388–$3,588/year compounded standard tier against PlexusDx Microdose GLP-1 Protocol at $1,548/year or Semaglutide Injection at $2,148–$2,748/year — with no separate membership fee. Question 3: Do you want the FDA-approved branded product specifically? Ro is the simplest path to Wegovy, Zepbound, or Foundayo without a separate membership; SHED’s brand-name lane offers them but adds a $125/month Shed Membership. Question 4: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option in this comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is SHED cheaper than Ro for GLP-1?

It depends on the lane. SHED’s compounded semaglutide injection at $149-$289/mo is comparable to Ro’s cash-pay Wegovy pill total ($39 first month + $149/month medication + $99/month membership) once you compare like-for-like total spend. For brand-name with insurance, Ro is meaningfully cheaper because the insurance concierge can get covered copays as low as $25/month. For cash-pay where price is the only variable, the PlexusDx Microdose GLP-1 Protocol at $129/mo flat undercuts both.

Is SHED compounded and Ro FDA-approved?

That shorthand is incomplete in 2026. SHED carries both compounded medications (injections, drops, lozenges, oral tablets) and FDA-approved branded medications (Wegovy, Zepbound, Foundayo) via its brand-name pathway. Ro is primarily focused on FDA-approved branded medication. PlexusDx Weight Management Protocols are compounded semaglutide and tirzepatide — the same active ingredients as Wegovy, Ozempic, Zepbound, and Mounjaro, but pharmacy-prepared rather than FDA-approved finished products.

Which platform is best if I hate injections?

If you want compounded oral options, SHED has the broadest compounded no-needle menu and PlexusDx offers Semaglutide Oral, Tirzepatide Oral, and the Microdose GLP-1 Protocol at $129/mo flat across capsule, troche, lozenge, and sublingual variants. If you want FDA-approved oral pills specifically, Ro carries the Wegovy pill and Foundayo at manufacturer-matched cash pricing.

Can I get Wegovy through SHED, Ro, or PlexusDx?

SHED offers Wegovy through its brand-name pathway with a $125/month Shed Membership added on top of medication. Ro offers Wegovy at $39 first month for the Ro Body membership plus $149/month for the Wegovy pill or $199/month for the pen, with potential covered-insurance copays as low as $25/month. PlexusDx does not dispense Wegovy itself but offers compounded semaglutide injection at $149/mo — same active ingredient, pharmacy-prepared rather than FDA-approved branded.

Does PlexusDx accept insurance?

No. PlexusDx is cash-pay across all six Weight Management Protocols, with no membership fee. HSA and FSA cards are accepted. Pricing is flat per protocol — $129/mo for Microdose GLP-1 up to $279/mo for Tirzepatide Oral — with no insurance billing or prior-authorization workflow. If reliable insurance coverage for FDA-approved branded GLP-1s is central to your plan, Ro’s insurance concierge is the structurally better starting point.

Why does PlexusDx run a genetic test the others don’t?

GLP-1 response varies measurably by genotype. The Precision Peptide Genetic Test covers 48 genes, 57 variants, and 34 weight-management insights including GIPR rs1800437 — the variant most associated with differential GLP-1 response — so the prescribing clinician can stratify titration before week one rather than learning from subjective tolerability over 8–12 weeks. It’s $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol.

Can I switch from SHED or Ro to PlexusDx mid-journey?

Yes. Cancel the current platform per its terms (SHED requires a 2-month minimum and 72-hour cancellation window; Ro is month-to-month with a 48-hour cancellation window before renewal), complete the PlexusDx intake, and a licensed clinician will review your history and prescribe. Talk to a clinician before changing medications, especially if you’re mid-titration. Many patients switch mid-journey based on what’s working — this is a normal pattern, not a red flag.

SHED vs Ro vs PlexusDx (2026): GLP-1 Pricing, Meds, and Genetic Personalization | PlexusDx